Sucampo Pharmaceuticals: What Can Investors Learn From The Mallinckrodt Acquisition?

12/29/17

Mallinckrodt to acquire Sucampo Pharmaceuticals for $1.2B. The cash tender offer equates to $18 per share.

Mallinckrodt to take ownership of Amitiza, a leading medicine servicing the branded constipation market (as well as other molecules for the orphan diseases niche).

This is an abbreviated version of the in-depth Integrated BioSci Report available in advance to our marketplace subscribers.

READ FULL ARTICLE HERE

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.